Advertisement
UK markets close in 7 hours 12 minutes
  • FTSE 100

    8,197.89
    -17.59 (-0.21%)
     
  • FTSE 250

    20,426.12
    -71.28 (-0.35%)
     
  • AIM

    787.66
    +0.30 (+0.04%)
     
  • GBP/EUR

    1.1832
    -0.0002 (-0.02%)
     
  • GBP/USD

    1.2790
    -0.0010 (-0.08%)
     
  • Bitcoin GBP

    52,904.99
    +126.80 (+0.24%)
     
  • CMC Crypto 200

    1,425.78
    +12.83 (+0.91%)
     
  • S&P 500

    5,421.03
    +45.71 (+0.85%)
     
  • DOW

    38,712.21
    -35.21 (-0.09%)
     
  • CRUDE OIL

    78.41
    -0.09 (-0.11%)
     
  • GOLD FUTURES

    2,330.60
    -24.20 (-1.03%)
     
  • NIKKEI 225

    38,720.47
    -156.24 (-0.40%)
     
  • HANG SENG

    18,115.02
    +177.18 (+0.99%)
     
  • DAX

    18,529.29
    -101.57 (-0.55%)
     
  • CAC 40

    7,828.28
    -36.42 (-0.46%)
     

BUZZ-GlaxoSmithKline Plc: Shingles vaccine could be better than Merck's - Cowen

** Drugmaker's U.S.-listed shares up 1.3 pct at $46.75 premarket, London-listed up nearly 2 pct

** Cowen & Co analysts say GSK's vaccine to treat shingles may be more effective than Merck (LSE: 0O14.L - news) 's

** Glaxo's vaccine HZ/su should be well positioned to capture market share from Merck's Zostavax if final data from a late-stage study shows HZ/su has better efficacy while treating older patients, Cowen says

** Final data from late-stage study expected in H1 2015

** Merck sold $765 mln worth Zostavax worldwide in 2014

** Barclays (LSE: BARC.L - news) raised its price target on European drugmakers, including GSK's London-listed stock

** GSK up nearly 2 pct on the LSE

** Through Monday, the U.S. stock had gained 10 pct since Dec. 18, when GSK reported early data from the late-stage study